ArticleThe Journal of clinical investigation2014
Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition.
Article in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- The impact of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes and chronic kidney disease: systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Obesity and the kidney: mechanistic links and therapeutic advances.Nature reviews. Endocrinology · 2024Review
- Liver or kidney: Who has the oar in the gluconeogenesis boat and when?World journal of diabetes · 2023Review
- Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class.International journal of molecular sciences · 2021Review
- Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History.International journal of molecular sciences · 2021Review
- Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.Journal of diabetes investigation · 2021Observational
- Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.Journal of diabetes investigation · 2021Review
- Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application.Pflugers Archiv : European journal of physiology · 2020Review
- The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.Cardiovascular diabetology · 2019Article
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.Redox biology · 2018 · on this mapArticle
- Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.Journal of diabetes investigation · 2017Review
- The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbADiabetes therapy : research, treatment and education of diabetes and related disorders · 2017Article
- Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus.Diabetology international · 2016Article
- Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.Drugs · 2015 · on this mapReview
- Renal effects of dapagliflozin in patients with type 2 diabetes.Therapeutic advances in endocrinology and metabolism · 2014Review
- SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease.Jornal brasileiro de nefrologiaReview
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
It is well known that glycemic control over time reduces microvascular and macrovascular complications in human subjects with type 2 diabetes. In addition, preclinical models of type 2 diabetes have demonstrated that long-term hyperglycemia exacerbates insulin resistance and reduces β cell function; therefore, therapies that reduce blood glucose levels are of great interest in not only controlling complications, but for restoring known defects in the pathogenesis of type 2 diabetes. Pharmacological inhibition of the sodium-glucose cotransporter 2 (SGLT2) reduces plasma glucose by limiting glucose absorption in the kidney and increasing glucose excretion in the urine. In this issue of the JCI, Merovci and colleagues and Ferrannini and colleagues independently report a paradoxical increase in endogenous glucose production in patients with type 2 diabetes following SGLT2 inhibition, despite an overall decrease in fasting plasma glucose. Together, these studies provide a unique insight into the effects of SGLT2 inhibition on whole body metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.